

Nanexa receives grant from VINNOVA for study with monoclonal antibodies

Nanexa AB today announced that the company has been granted funding under the VINNOVA project "Verification in Test Center, Part III" for a maximum amount of SEK 290,000. The funds will be used for an internal research project at Nanexa with the aim of coating monoclonal antibodies (mAbs) with PharmaShell®.

The project is entitled: "A proof-of-concept study of applying prolonged-release coatings onto monoclonal antibodies using the PharmaShell® technology".

"We are seeing increased interest in PharmaShell among the really big pharmaceutical companies, including applications with biologics such as peptides, proteins, polysaccharides and not least mAbs. It is therefore very gratifying that we can now conduct our own studies with mAbs and demonstrate the benefits of PharmaShell in this expansive and very interesting field," says David Westberg, CEO of Nanexa.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing parenteral drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Nanexa receives grant from VINNOVA for study with monoclonal antibodies](#)